
    
      A retrospective analysis of a prospective, multicenter, industry-sponsored, open-label,
      uncontrolled, community-based clinical trial of combination of peginterferon alfa-2a and
      ribavirin (Pegasys Expanded Access Program) conducted at 6 tertiary referral centers in Korea
      between 2003 and 2004 and a cohort of hepatitis C patients who were treated in a single
      tertiary referral hospital (Asan Medical Center, Seoul, Korea) between 2004 and 2008
    
  